Vaccinex, Inc.

University of Rochester

Albert Einstein College of Medicine

The Sydney Children's Hospital Network

Maurice Zauderer

Ernest S Smith

Elizabeth E Evans

Mark Paris

William J Bowers

Alan Jonason

Renee A Kirk

Tracy Pandina

Terrence Lee Fisher

Angelica Moksa

Masaru Yoshida

Terrence L Fisher, Sr

Angelica A Cornelison

Steven A Porcelli

Leslie A Croy

Melinda A Borrello

Jean-Pierre Mach

Maria G M Scrivens

Leslie A Balch

Alena Donda

Koji Yamamoto

Yilin Mao

Wendy Gold

Bruno Robert

Maria Scrivens

Valerie Cesson

Angelika Moksa

Deepak M Sahasrabudhe

Mark J Paris

Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.

Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis

Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.

Human anti-semaphorin 4D antibody

Provided herein are methods for alleviating symptoms in a subject having Rett syndrome, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D).

Use of semaphorin-4D binding molecules for the treatment of Rett syndrome

This disclosure provides a method for inhibiting, delaying, or reducing malignant cell growth in a subject with cancer, comprising administering to the subject a combination therapy comprising an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an epigenetic modulating agent, e.g., a histone deacetylase (HDAC) inhibitor (HDACi) a DNA methyltransferase (DNMT) inhibitor (DNMTi), or any combination thereof. The disclosure further provides a pharmaceutical composition comprising the combination therapy.

Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent

Provided herein are methods for decreasing blood-brain barrier permeability in a subject with a neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor.

Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability

Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases

Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.

Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.

Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunit

Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases

Provided herein are methods for promoting neurogenesis in neural tissue of a patient exhibiting at least one symptom of a central nervous system disorder, the method comprising administering to a subject in need thereof an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D).

Use of semaphorin-4D binding molecules to promote neurogenesis following stroke

The invention is directed to compositions and methods related to proteins that are physically associated with ceramide-like glycolipids for use as activators of NKT cells. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.

Modified glycolipids and methods of making and using the same

Methods for treating diseases associated with chemokine (C-X-C motif) ligand 13 (CXCL13) expression, including certain autoimmune and inflammatory diseases such as Sjogren's syndrome are provided herein. The methods comprise administering to a subject in need thereof an effective amount of an agent that inhibits CXCL13 activity. According to aspects of the invention illustrated herein, there is provided a method of treating, preventing, or reducing the exacerbation of a B-cell-mediated inflammatory condition in a subject, including administering to a subject an effective amount of an isolated binding molecule which specifically binds to CXCL13, wherein said molecule prevents or inhibits CXCL13 activity.

Methods for the treatment of B cell-mediated inflammatory diseases

Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.

Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency

Growing community of inventors

Pittsford, NY, United States of America

Maurice Zauderer